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Abstract 
Background: Multidimensional fatigue syndrome (MFS) is referred to 
as extreme inability accompanied by decline in physical functional 
capacity and impairment of intellectual function, such as loss of 
concentration. Elderly people are more prone to MFS comparing to 
other age groups. It is expected that adequacy of dialysis affect the 
process of MFS among patients under dialysis. The purpose of the 
study is to assess MFS and its association to adequacy of dialysis 
among dialysis patients. 
Methods: This cross-sectional study is conducted on patients under 
dialysis aged 50 years and above. Convenience sampling was used to 
collect the data. The main instrument of the study was 
Multidimensional Fatigue Symptom Inventory- Short Form (MFSI-SF). 
To assess subjects’ mental status Mini Mental Status Exam (MMSE) 
was applied. Subjects with MMSE greater than 18 were included in the 
study. 
Results: The participants’ range of age were 50 to 81 and the mean 
age of them were 62 years old. According to the findings of this study, 
of 43 eligible participants, 33 patients (76.7%) were suffering from 
different level of MFS. Moreover, adequacy of dialysis among dialysis 
patients were favorably high in 10 patients (23.2%), moderate in 24 
patients (55.8%) and low in 9 patients (21%). Multiple regression 
showed that MFS (P=0.01) and anemia (P=0.04) were significantly 
associated with adequacy of hemodialysis among elderly patients.  
Conclusions: This study is in line with hypothesis of the study that 
adequacy of hemodialysis reduces MFS among elderly patients under 
hemodialysis. It is highly recommended that adequacy of hemodialysis 
and Hb level should be under close monitoring to overcome MFS 
among senior citizens under hemodialysis treatment. 
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Introduction 
The number of patients on hemodialysis dialysis is 
increasing in many countries.1-3 Previous studies have 
concluded that ESRD seems to be more prevalent at higher 
ages.2 Fatigue is one of the most frequent complaints of 
dialysis patients and is associated with impaired health-related 
quality of life.4 ESRD patients undergoing chronic 
hemodialysis suffer from numerous complications including 
fatigue.5-7 The prevalence of fatigue ranges from 60% to as 
high as 97% in patients on long-term renal replacement 
therapy.4-7 Previous researches suggest that fatigue is a 
multidimensional phenomenon, composed of physical, 
psychological, and possibly other aspects.7-8 Multidimensional 
Fatigue Syndrome (MFS) is referred to as extreme inability 
accompanied by decline in physical functional capacity and 
impairment of intellectual function, such as loss of 
concentration.7-9 Contrary to the normal physiological 
tiredness, it is not relieved by sufficient sleep or rest.10 Fatigue 
is perceived as a potentially treatable symptom requiring 
adequate diagnosis and interventions.10,12 Multidimensional 
Fatigue Syndrome was first introduced to assess fatigue in 
patients’ with cancer or under chemotherapy.10 Few studies 
have investigated Multidimensional Fatigue Syndrome among 
End Stage Renal Disease (ESRD) patients. While these 
findings are important, they do little to expand our knowledge 
regarding the Multidimensional Fatigue Syndrome among 
elderly patients on hemodialysis.13-14 Moreover, elderly patients 
under treatment of hemodialysis are generally neglected in 
previous related studies. It is recommended to evaluate whether 
dialysis is removing enough urea. The dialysis clinic should 
periodically (normally once a month) test a patient’s blood to 
measure dialysis adequacy.2;12 The most reliable method to 
assess dialysis adequacy is to measure Kt/V as an index for 
dialysis adequacy. In medicine, Kt/V is a number used to 
quantify hemodialysis, where K is dialyzer clearance of urea, 
t is the dialysis time and V is the volume of distribution of urea, 
approximately equal to patient's total body water.15  
Since, adequacy of dialysis can promote quality of life 
among patient with ESRD under dialysis,13 it is imperative to 
explore its determinants such as Multidimensional Fatigue 
Syndrome. The purpose of this study was to investigate the 
association of adequacy of hemodialysis and multidimensional 
fatigue syndrome among near old ESRD patients under 
hemodialysis treatment.   
Materials and Methods  
This cross-sectional study was conducted in referral 
dialysis center covering urban and rural area with population of 
some 140000, people. More than 70 patients were under 
treatment of hemodialysis at the time of the study. Subjects of 
this study were 48 patients 50 years old and above. Other 
inclusion criteria were being under hemodialysis during last 12 
months. Of all 48 eligible subjects, one patient declined to 
participate the research process and four subjects excluded 
from the study because of low Mini-Mental Status Examination 
(MMSE) score (below 18). The remaining 43 subjects were 
under continuous hemodialysis three sessions a week, each 
lasting 3-4 hours.  
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In this study all patients were treated by bicarbonate 
hemodialysate with conventional biocompatible membrane. 
The calcium content of dialysate varied between 1.5 and 1.75 
mmol / L. The dialysis process was the same in terms of 
dialysate content and temperature, daytime and standard vessel 
access. 
A questionnaire containing information regarding 
demographics, hemodialysis treatment dose, and other 
comorbid conditions was applied. In addition, the 
Multidimensional Fatigue Symptom Inventory- Short Form 
(MFSI-SF) was applied to assess subjects’ fatigue. The 
Multidimensional Fatigue Symptom Inventory- Short Form is a 
30-item of the MFSI that yield scores for the empirically 
derived subscales.18 Preliminary research suggests that it has 
acceptable psychometric properties and may be used as a 
substitute for the MFSI when time constraints and scale length 
are of concern.7-8;14 In fact, the Multidimensional Fatigue 
Symptom Inventory- Short Form (MFSI-SF) is a self-report 
instrument designed to measure fatigue. It covers the 
dimensions of general, physical, mental, emotional fatigue and 
vigor.7 Each dimension of fatigue is assessed by 6 questions, 
separately. For total scoring of fatigue, the scores of all 
subscales including general, physical, mental, emotional 
fatigue and vigor are added. Scoring the items in subscale of 
vigor is inversed. The range of scores in MFSI-SF is between 0 
and 120. Scores of 0 to 30 indicate no multidimensional fatigue 
syndrome. Subjects’ scores of 31 to 60, 61 to 90 and 91 to 120 
show low, moderate and high MFS, respectively.7-8  
In order to assess validity and reliability of the scale, 2 
bilingual faculty members and one native English speaker who 
was completely unaware of the test and its purpose, conducted 
the forward- backward translation process. Ten faculty 
members assessed the translated version of the scale. They 
approved face and content validity of the translated version of 
the scale, after some minor modifications.  
The National Kidney Foundation recommend that adult 
hemodialysis patients receive a minimum dialysis dose by 
single-pooled Kt/V (spKt/V) of 1.2 or greater15. In medicine, 
Kt/V is an equation used to assess the quantity of hemodialysis 
and treatment adequacy, where K is dialyzer clearance of urea, 
t is the dialysis time and V is the volume of urea. In the context 
of hemodialysis, Kt/V is dependent on the pre- and post-
dialysis BUN concentration. The US National Kidney 
Foundation Kt/V target is ≥1.3.16 
Hemoglobin (Hb) is the main parameter to assess anemia. 
17-18 In fact, anemia is a deficiency of oxygen-carrying red 
blood cells, measured in unit volume concentrations of Hb.17 A 
recent study (2014) defines anemia as an Hb level <12 g/dL for 
women and <13 g/dL for men. This figure for hemodialysis 
patient is lowered to 10 mg/dl. Moreover, anemia may be 
associated with the aging process, as its prevalence increases 
with age.19  
All data were entered into a database and were verified by a 
second independent person. Statistical analysis was performed 
using SPSS version 19. Descriptive statistics was applied to 
calculate Mean (M) and Standard Deviation (SD) of interval 
variables. In addition, univariate analysis (Chi-Square) was 
applied for correlated variables of Multidimensional Fatigue 
Syndrome. Multiple logistic regression analysis was used to 
calculate Kt/V and Hb. adjusted odds ratios for all variables. 
Variables with P<0.05 were chosen to be entered into the final 
model. 
Results 
The participants’ range of age was 50 to 81 and the mean 
age of them were 62 years old. The number of male and female 
subjects of the study were 25 (58%) and 18 (42%), 
respectively. The length of hemodialysis treatment ranged from 
1to 22 years. The mean (M) and standard deviation (SD) of 
interval variables of the study including five subscales of MFS 
score among subjects of the study are summarized in Table 1.  
Table 2 presents Chi-Square results for correlated variables 
of multidimensional fatigue syndrome. The results of the study 
regarding adequacy of hemodialysis, indicated 21 percent of 
the subjects (n=9) were suffering from very low adequacy of 
hemodialysis (Kt/V≤1.2), 56 percent (n=24) subjects had 
normal adequacy of hemodialysis (Kt/V>1.2-1.6) and the 
remaining 23% (n=10) of the subjects had high adequacy of 
hemodialysis (Kt/V≤1.7). Chi-Square results showed that there 
was a significant relationship between participants’ adequacy 
of hemodialysis and MFS score (P>0.001) of all 43 participants 
of the study, 19 patients (44%) had hemoglobin lower that 10 
mg/dL and were under treatment of Erythropoietin at the time 
of study.0. Moreover, the results indicatd a significant 
relationship between subjects’ level of hemoglobin and MFS 
score (P=0.04). 
The results of multiple logistic regressions are shown in 
Table 3. According to Table 3, after controlling for covariates, 
lower Hb levels and low adequacy of hemodialysis were 
significantly associated with MFS. Based on, multiple logistic 
regressions showed that one unit decrease in Kt/V would 
increase the risk of fatigue by 1.85 times (95% CI 1.73, 1.96). 
Moreover, any one unit decrease in Hb would increase the 
fatigue by 1.65 times (95% CI 1.48, 1.85). 
Table 1. Mean and standard deviation of the participants’ 
characteristics  
 Range Mean SD 
Age (year) 50 to 81 62.3 4 
Length of Dialysis (year) 1-22 7.6 2 
Level of Hb (mg/dL) 6-12.3 9.5 2 
Kt/ V 0.7- 1.8 1.1 0.6 
Calcium 6.2- 10.3 8.3 1.6 
MFS    
 General 4-25 21 4 
 Physical 5-28 22 5 
 Mental 5-26 18 3 
 Emotional 6-24 22 5 
 Vigor 5-23 23 6 
 Total 25-126 106 4.6 
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Table 2. Chi-Square analysis results for determinants of MFS  
Outcome Variables 
N (%) 
MFS  
No (%) Low (%) Moderate (%) High (%) P.V 
Age 
50-60 18 (41) 3 (14) 5 (28) 6 (34) 4 (22) 0.31 
61-70 15 (35) 4 (27) 3 (20) 3 (20) 5 (33) 
 
>71 10 (23) 3 (30) 2 (20) 2 (20) 3 (30) 
Gender 
Male 25 (58) 5 (20) 4 (16) 8 (32) 7 (28) 0.13 
Female 18 (42) 3 (17) 4 (22) 6 (33) 5 (28)  
Length of Dialysis 
< 2 years 12 (28) 2 (17) 4 (34) 3 (25) 3 (25) 0.09 
2 -10 years 20 (47) 6 (30) 4 (20) 5 (25) 5 (25) 
 
≥ 10 years 11 (26) 3 (27) 2 (18) 3 (27) 3 (27) 
Level of Education 
Illiterate 14 (33) 3 (21) 4 (27) 4 (27) 3 (21) 0.21 
Primary 22 (51) 5 (23) 7 (32) 6 (27) 4 (18) 
 
High School 7 (16) 3 (43) 2 (29) 1 (14) 1 (14) 
Level of Hb (mg/dL) 
<Below 10 19 (44) 3 (16) 3 (16) 7 (37) 6 (32) 0.04* 
≥10 24 (56) 8 (33) 9 (37) 5 (21) 2 (8)  
Diabetes Yes 26 (60) 6 (23) 6 (23) 7 (27) 7 (27)  
No 17 (40) 5 (29) 4 (24) 3 (18) 5 (29)  
Hypertension 
Yes 22 (51) 7 (32) 5 (23) 6 (27) 4 (18)  
No 21 (49) 4 (19) 6 (29) 6 (29 ) 5 (24)  
Kt/ V 
Low 9 (21) 1 (11) 2 (22) 2 (22) 4 (45) 0.00* 
Normal 24 (56) 8 (34) 7 (29) 5 (21) 4 (26) 
 
High 10 (33) 5 (50) 2 (20) 2 (20) 1 (10) 
Calcium 
Low 27 (63) 8 (30) 6 (22) 7 (26) 6 (22) 0.17 
Normal 16 (37) 5 (31) 4 (25) 4 (25) 3 (19)  
*P<0.05 
Table 3. The results of the multiple logistic regression analysis 
of the possible determinants 
 
Odd’s ratio 
95% CI 
P.V 
Lower Upper 
Kt/V 1.85 1.73 1.96 0.00 
Anemia 1.65 1.48 1.85 0.04 
     
Discussion 
This is one of the first studies from Iran, presenting the 
prevalence of MFS. The outstanding finding of the study was 
the impact of adequacy of hemodialysis on MFS. To our 
knowledge this study is the first study to explore the 
relationship between hemodialysis and MFS. Findings of the 
study are in accordance with Lobbedez (2008) study which 
concluded that fatigue score were high in elderly dialysis 
compared with nondialysis patients. In addition, this study 
found that anemia was common among participants of the 
study. The reason behind the correlation of MFS with anemia 
among patients with chronic kidney disease (CKD) is evident. 17,21 
Anemia results from insufficient production of erythropoietin 
by the kidneys and is a common complication of chronic 
kidney disease.14,21 Anemia is most pronounced in patients with 
ESRD requiring dialysis, and has been reported to be 
associated with a variety of symptoms including fatigue, 
muscle weakness, impaired physical functioning, shortness of 
breath and depression.4-5,14,21 Moreover, the use of 
Erythropoietin Stimulating Agents (ESA) to correct anemia in 
dialysis patients has been shown to improve health related 
quality of life, fatigue, exercise tolerance and work capacity.8,13,18,21 
The routine protocol for anemia management in Iran includes 
recombinant α-erythropoietin and iron source for intravascular 
iron.3 In fact, fatigue is a determinant element of quality of life. 
Erythropoiesis-stimulating agent therapy in patients with renal 
insufficiency and cancer revealed a consistently positive 
relationship between health’s related quality of life and 
hematocrit levels, with the strongest effect on the 
energy/fatigue domains.18 These findings were confirmed by a 
meta-analysis of the impact of epoetin alfa in patients with 
chronic kidney disease.22 
The finding of this study is accordance with previous 
studies which concluded that dialysis patients who received 
Erythropoiesis-stimulating agents to a target hemoglobin of 
10g/dL had significantly lower fatigue levels after the target 
hemoglobin was reached.14,18,22 In addition, Canadian 
Erythropoietin Study Group found that patients treated with 
ESA also had a significant decrease in fatigue from baseline to 
2 month follow-up.21 A large longitudinal study found that 
patients who received EPO to achieve a normal hemoglobin 
level (13.0-15.0 g/dL) had significantly better vitality scores as 
measured by the SF-36.11,23 There were some drawback for this 
study. The main limitation of the study was limited number of 
patients in the age range of participants 50 years old and above. 
Moreover, participants of the study were not selected 
randomly. Future studies are suggested to work on a large, 
randomly selected sample of elderly patients. In this study, 
researchers had access to limited number of elderly patients 
under treatment of hemodialysis.  
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